In line with the phenotype of Ptpn22-/- mice, adoptive transfer of Ptpn22-deficient OT-I T cells was shown to control the growth of OVA peptide-expressing lymphoma and ovarian carcinoma tumors more effectively and also enhance the efficacy of a TGFβ blocking antibody (82, 83). This evidence concerns the gene PTPN22 and ovarian carcinoma.